Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 25:8:212583.
doi: 10.7573/dic.212583. eCollection 2019.

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Paolo Antonio Ascierto  1 , Dirk Schadendorf  2
Affiliations

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Paolo Antonio Ascierto et al. Drugs Context. .
No abstract available

Keywords: advanced disease; basal cell carcinoma; cutaneous squamous cell carcinoma; immunotherapy; nonmelanoma skin cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: Dr Ascierto reports grants and personal fees from BMS, grants and personal fees from Roche-Genentech, personal fees from MSD, grants and personal fees from Array, personal fees from Novartis, personal fees from Merck Serono, personal fees from Pierre Fabre, personal fees from Incyte, personal fees from Genmab, personal fees from NewLink Genetics, personal fees from Medimmune, personal fees from AstraZeneca, personal fees from Syndax, personal fees from Sun Pharma, personal fees from Sanofi, personal fees from Idera, personal fees from Ultimovacs, personal fees from Sandoz, personal fees from Immunocore, outside the submitted work. Dr Schadendorf reports personal fees and other from Sanofi/Regeneron, during the conduct of the study; personal fees from Amgen, personal fees from Boehringer Ingelheim, personal fees from Leo Pharma, personal fees and other from Roche, personal fees and other from Novartis, personal fees from Incyte, personal fees and other from MSD, personal fees from 4SC, personal fees from AstraZeneca, personal fees and other from BMS, personal fees from Pierre Fabre, personal fees and other from Merck-EMD, personal fees from Pfizer, personal fees and other from Philiogen, personal fees from Array, outside the submitted work. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2019/03/dic.212583-COI.pdf

References

    1. AIRTUM Analisi epidemiologica e caratterizzazione morfologica di pazienti affetti da tumore della cute non melanoma da registro nazionale AIRTUM. https://www.registri-tumori.it/cms/pubblicazioni/report-i-tumori-cutanei.
    1. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989;262(15):2097–2100. - PubMed
    1. Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007. doi: 10.1016/j.ejca.2015.06.110. - DOI - PubMed
    1. Harwood CA, Proby CM, Inman GJ, et al. The promise of genomics and the development of targeted therapies for cutaneous squamous cell carcinoma. Acta Derm Venereol. 2016;96(1):3–16. doi: 10.2340/00015555-2181. - DOI - PubMed
    1. Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96:34–43. doi: 10.1016/j.ejca.2018.01.075. - DOI - PubMed